After a 9–3 advisory committee rejection, Capricor is asking the FDA to reconsider deramiocel with new 24-month upper-limb data.
Key Takeaways
- Deramiocel (CAP-1002) is an investigational allogeneic cardiac-derived cell therapy for Duchenne muscular dystrophy (DMD).
- An FDA advisory committee voted 9–3 against the evidence supporting efficacy, mainly because of concerns about cardiac benefit and changes in data analysis.
- Capricor will submit new 24-month upper-limb function data, giving the FDA another opportunity to assess the therapy.
Data Snapshot
| Item | Details |
|---|---|
| Therapy | Deramiocel (CAP-1002) |
| Developer | Capricor Therapeutics |
| Modality | Allogeneic cardiosphere-derived cell therapy |
| Disease | Duchenne muscular dystrophy (DMD) |
| Phase 3 trial | HOPE-3 |
| Functional endpoint | Performance of the Upper Limb 2.0 (PUL 2.0) |
| Advisory vote | 3 Yes / 9 No |
| New submission | 24-month upper-limb data |
| Previous FDA decision date | August 22, 2026 |
Deramiocel consists of cardiosphere-derived cells (CDCs) obtained from donor human heart tissue. Capricor is developing the therapy to address skeletal and cardiac muscle deterioration in DMD. (Capricor Therapeutics)
What Happened
Capricor said the U.S. Food and Drug Administration (FDA) is willing to review additional 24-month data for deramiocel after a difficult regulatory review. The new submission will focus on upper-limb function, the main functional endpoint of the Phase 3 HOPE-3 study. (Reuters report)
The development follows a July 29 meeting of the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee. The panel voted 3 in favor and 9 against whether the available evidence demonstrated deramiocel’s effectiveness for cardiomyopathy associated with DMD. (FDA advisory committee materials)
The FDA had previously been expected to act by August 22, but review of the additional data is expected to delay that timeline.
Why It Matters
The negative advisory vote was driven primarily by questions about efficacy, not a newly identified safety problem.
FDA reviewers questioned changes made to the statistical analysis after the late-stage trial was completed, including how upper-limb and cardiac outcomes were evaluated. They also questioned whether some patients clearly had DMD-related cardiomyopathy because average cardiac function was relatively preserved at baseline. (Reuters report)
Upper-limb function, however, became an important point of differentiation. HOPE-3 evaluated this using PUL 2.0 (Performance of the Upper Limb 2.0), a standardized scale used to measure arm and hand function in DMD. Capricor reported that HOPE-3 met its primary endpoint, and some advisory committee members viewed the skeletal-muscle data more favorably than the cardiac evidence. (Capricor clinical update)
The FDA’s willingness to review longer-term data therefore gives Capricor another chance to show whether the functional benefit remains convincing over time.
BP View
Deramiocel represents a different strategy from gene replacement or exon-skipping therapies. Rather than correcting the underlying dystrophin mutation, it aims to influence the inflammatory and tissue-damage environment that contributes to progressive muscle decline.
The new 24-month data do not erase the advisory committee’s concerns. They simply provide another opportunity to determine whether the upper-limb benefit becomes more convincing with longer follow-up.
For patients and families living with DMD, the central question is not whether deramiocel can survive the regulatory process, but whether the evidence can clearly show that treatment preserves meaningful physical function as the disease progresses.
Related Post
For another recent example of regulators evaluating promising but incomplete clinical evidence, read our previous analysis of Bristol Myers Squibb’s accelerated approval of Zenbexus in multiple myeloma.
About BP
Biopharma Perspective (BP) explains global biopharma news through strategic, clinical and market perspectives.
Leave a Reply